Population-based case-control study of chinese herbal products containing aristolochic acid and urinary tract cancer risk

Journal of the National Cancer Institute

Volumn 102, Issue 3, 2010, Pages 179-186

  Lai, Ming Nan ^a   Wang, Shuo Meng ^b   Chen, Pau Chung ^a   Chen, Ya Yin ^c   Wang, Jung Der ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; HERBACEOUS AGENT;

ADULT; AGED; ARISTOLOCHIA FANGCHI; ARISTOLOCHIA MANSHURIENSIS; ARTICLE; ASARUM HETEROTROPOIDES; CANCER RISK; CAULIS ARISTOLOCHIAE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EXPOSURE; DRUG INDUSTRY; DRUG SYNTHESIS; DRUG USE; FEMALE; FRUCTUS ARISTOLOCHIAE; GROUPS BY AGE; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RADIX ARISTOLOCHIAE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TAIWAN; URINARY TRACT CANCER; URINARY TRACT INFECTION;

ADULT; AGED; ARISTOLOCHIC ACIDS; CARCINOGENS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RESEARCH DESIGN; RISK FACTORS; TAIWAN; UROLOGIC NEOPLASMS;

EID: 76349101626     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp467     Document Type: Article

References (41)

1. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fbrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387-391.
2. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identifcation of aristolochic acid in Chinese herbs [letter]. Lancet. 1994; 343(8890):174.
3. Cosyns JP. Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Saf. 2003;26(1):33-48.
4. Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686-1692.
5. Cosyns JP, Jadoul M, Squiffet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis. 1999; 33(6):1011-1017.
6. Arlt VM, Stilborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002; 17(4):265-277
7. International Agency for Research on Cancer. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002;82(February):551.
8. Kessler DA. Cancer and herbs. N Engl J Med. 2000;342(23):1742-1743.
9. U.S. Food and Drug Administration. Dietary supplements, Alert: Dietary Supplements: Aristolochic Acid, FDA Concerned About Botanical Products, Including Dietary Supplements, Containing Aristolochic Acid. http://www.fda.gov/Food/DietarySupplements/Alerts/ucm095272.htm. Accessed Nov. 27, 2009.
10. Committee on Chinese Medicine and Pharmacy, Department of Health. Regulation of drugs [in Chinese]. http://www.ccmp.gov.tw/public/public. asp?selno=816&relno=816&level=C 2003. Accessed January 10 2008.
11. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive interstitial renal fbrosis associated Chinese herbal drug. Am J Kidney Dis. 2000; 35(2):313-318.
12. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial fbrosis associated with Chinese herbal medications. Am J Nephrol. 2001;21(6):441-448.
13. Yang HY, Lin JL, Chen KH, et al. Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol. 2006; 19(1):111-114.
14. Taiwan Yearbook 2004, Public Health. Health Insurance. Taipei, Taiwan. http://www.gio.gov.tw/taiwan-website/5-gp/yearbook/2004/P243.htm#2. 2004. Accessed June 27, 2009.
15. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 1997;13(5):291-298.
16. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985;45(11, pt 2):5895-5899.
17. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer. 1986;53(3):399-405.
18. National Health Research Institutes. National Health Insurance Re-search database. http://www.nhri.org.tw/nhird/date-01.html#-edn1. 2003. Accessed January 3, 2009.
19. Centers for Disease Control and Prevention, Atlanta, Georgia, 1979. International Classifcation of Diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm. Accessed October 21, 2009.
20. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant. 1999;14(12):2892-2897.
21. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001;12(6):690-694.
22. Castelao JE, Yuan J-M, Gago-Dominguez M, et al. Non-steroidal anti-infammatory drugs and bladder cancer prevention. Br J Cancer. 2000; 82(7):1364-1369.
23. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinfammatory drugs. N Engl J Med. 1994;331(25):1675-1679.
24. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999;81(3):542-548. (Pubitemid 29458812)
25. Committee on Chinese Medicine and Pharmacy, Department of Health. Unifed formulas 2002 [in Chinese]. http://www.ccmp.gov.tw/public/public.asp?selno= 492&relno=492&level=C. Accessed October 22 2009.
26. Hsu YH, Tseng HH, Wen KC. Determination of aristolochic acid in Fangchi radix [in Chinese]. Ann Rept NLFD Taiwan R O C. 1997;15:136-142.
27. Tung CF, Ho YL, Tsai HY, Chong YS. Studies on the commonly misused and adulterated Chinese crude drug species in Taiwan [in Chinese]. Chin Med Coll J. 1999;8(1):35-46.
28. Deng JS. Quality Evaluation of Fang-Ji and Analysis of Marker Constituents [dissertation] Taichung, Taiwan: Institute of Chinese Pharmaceutical Sciences, China Medical University; 2002:75-77.
29. Chuang MS, Hsu YH, Chang HC, Lin JH, Liao CH. Studies on adulteration and misusage of marketed Akebiae caulisn [in Chinese]. Ann Rept NLFD Taiwan ROC. 2002;20:104-119.
30. Jong TT, Lee MR, Hsiao SS, et al. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/ atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal. 2003;33(4):831-837.
31. Hsu YH, Lo CF, Chang HC, Lin JH. Studies on adulteration and misusage of Asari radi in the market [in Chinese]. Ann Rept NLFD Taiwan ROC. 2003;21:153-167.
32. Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83(3):346-351.
33. Jiang X, Castelao JE, Groshen S, et al. Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer. 2009;100(5): 834-839.
34. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology. 2009;14(2):227-234.
35. Taiwan Cancer Registry. Cancer incidence rate in Taiwan, 1998-2002 [in Chinese] 2009, http://crs.cph.ntu.edu.tw/main.php?Page=A5. Accessed October 22, 2009.
36. Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer. 1999;85(6):1342-1344.
37. Carroll PR. Urothelial carcinoma: cancers of the bladder, ureter and renal pelvis. In: Tanagho EA, McAninch JW, eds. General Urology. 14th ed. Philadelphia, PA: Prentice-Hall Int; 1995:353-371.
38. Lemy A, Rorive S, Zlotta A, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis. 2008;51(3):471-477.
39. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, Wang JD. The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf. 2008;17(6):609-619.
40. Bureau of Health Promotion, Department of Health, Taiwan. Annual report 2007 [in Chinese]. http://health99.doh.gov.tw/educzone/edu-detail. aspx?catid=21592. 2007. Accessed July 20 2009.
41. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephrop-athy: a worldwide problem. Kidney Int. 2008;74(2):158-169.